Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx HoldingsWGS +0.79%65 Return-on-Tangible-Asset is -20.33% as of Jun. 2026. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 212 Medical Diagnostics & Research companies, GeneDx Holdings ranks worse than 75.47% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. GeneDx Holdings's annualizedNet Income for the quarter that ended in Jun. 2026 was $-71.0 Mil. GeneDx Holdings's average total tangible assets for the quarter that ended in Jun. 2026 was $349.1 Mil. Therefore, GeneDx Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -20.33%.
The historical rank and industry rank for GeneDx Holdings's Return-on-Tangible-Asset or its related term are showing as below:
WGS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -127.91 Med: -62.39 Max: -6.98
Current: -32.77
During the past 7 years, GeneDx Holdings's highest Return-on-Tangible-Asset was -6.98%. The lowest was -127.91%. And the median was -62.39%.
WGS's Return-on-Tangible-Asset is ranked worse than 75.47% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.09
vs WGS: -32.77
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
GeneDx Holdings Return-on-Tangible-Asset Related Terms
GeneDx Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for GeneDx Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WGS vs NEO, CDNA, PSNL: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, GeneDx Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -20.33% mean?
GeneDx Holdings (WGS) has a Return-on-Tangible-Asset of -20.33% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on GeneDx Holdings and its competitors. According to the industry distribution chart, GeneDx Holdings ranks #160 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 75.5%.
Is GeneDx Holdings' Return-on-Tangible-Asset too high?
GeneDx Holdings' current Return-on-Tangible-Asset is -20.33%. Based on the distribution chart, GeneDx Holdings ranks #160 out of 212 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Return-on-Tangible-Asset compare to NEO and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #160 out of 212 companies for Return-on-Tangible-Asset. This places GeneDx Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on GeneDx Holdings and its competitors. GeneDx Holdings's current Return-on-Tangible-Asset is -20.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $91.04 — trading 23.4% above its estimated fair value. The current Return-on-Tangible-Asset is -20.33%. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Return-on-Tangible-Asset is -20.33% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $91.04 is trading 23.4% above its estimated GF Value™ of $73.77.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
Return-on-Tangible-Asset: -20.33%
GF Value™: $73.77 vs. price of $91.04 (23.4% above fair value)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score
Get the complete analysis for WGS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
